---
layout: minimal-medicine
nav_exclude: true
title: Inotuzumab Ozogamacin
---

# Inotuzumab Ozogamacin

**Generic Name:** Inotuzumab ozogamicin

**Usage:** Inotuzumab ozogamicin is a targeted therapy used to treat:

* **Relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) in adults.** This means it's used for adults whose ALL has returned after treatment (relapsed) or hasn't responded to treatment (refractory).  It's often used in combination with other chemotherapy drugs.
* **CD22-positive ALL in pediatric patients (in specific circumstances):**  It might be used in younger patients, but this is typically only in specific situations determined by a physician based on disease characteristics and response to other treatments.  It's not a first-line treatment for children with ALL.


**Side Effects:**  Inotuzumab ozogamicin can cause a wide range of side effects, some mild and others severe.  The most common include:

* **Infections:**  A significantly increased risk of serious infections due to immunosuppression.
* **Low blood cell counts (cytopenias):**  This includes neutropenia (low neutrophils, increasing infection risk), thrombocytopenia (low platelets, increasing bleeding risk), and anemia (low red blood cells, causing fatigue).
* **Nausea and vomiting:**  Often managed with anti-nausea medication.
* **Fatigue and weakness:** Common side effects of chemotherapy.
* **Liver problems:**  Elevated liver enzymes are common; severe liver damage is possible.
* **Kidney problems:**  Changes in kidney function may occur.
* **Tumor lysis syndrome (TLS):** A serious complication where the rapid breakdown of cancer cells releases harmful substances into the bloodstream.
* **Cardiac toxicity:**  Rare but potentially serious heart problems.
* **Hepatotoxicity:** Liver damage.
* **Hypersensitivity reactions:** Allergic-type reactions.
* **Mucositis:**  Inflammation and sores in the mouth and throat.

This is not an exhaustive list, and the severity of side effects can vary greatly between individuals.  It's crucial to report any new or worsening symptoms to your doctor immediately.


**How it Works:** Inotuzumab ozogamicin is a type of antibody-drug conjugate (ADC). It works by targeting CD22, a protein found on the surface of many leukemia cells. The "antibody" part (inotuzumab) binds specifically to the CD22 protein. The "drug" part (calicheamicin) is a potent cytotoxic agent (a substance that kills cells). Once the inotuzumab part attaches to the CD22 protein on the leukemia cell, the calicheamicin is released, entering the cell and causing DNA damage, ultimately leading to cell death.


**FAQs:**

* **Q: Is Inotuzumab ozogamicin a cure for ALL?** A: No, it's not a cure, but it can induce remission (reduction or disappearance of cancer symptoms) in some patients.
* **Q: How is Inotuzumab ozogamicin administered?** A: It's administered intravenously (IV) by a healthcare professional.
* **Q: What are the long-term effects of Inotuzumab ozogamicin?** A: Long-term effects are not fully known, but potential risks include secondary cancers and organ damage.  Close monitoring is crucial.
* **Q: Who should not take Inotuzumab ozogamicin?** A: Patients with severe hypersensitivity to the drug or severe pre-existing organ damage are generally not candidates.  Your doctor will assess your suitability.
* **Q: What monitoring is required during treatment?** A: Regular blood tests to monitor blood counts, liver and kidney function, and other vital signs are essential.  Heart function may also be monitored.


**Disclaimer:** This information is for general knowledge and does not constitute medical advice.  Always consult with a healthcare professional for diagnosis and treatment of any medical condition.  The specific usage, side effects, and risks of Inotuzumab ozogamicin may vary based on individual patient factors and the healthcare professional's assessment.


**Note:** This information is AI-generated or crowd-sourced and may not be accurate. Please consult a medical professional for verified advice.